Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q1 EPS of ($0.57), $0.05 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $3.21 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.